Management of the thrombotic risk associated with COVID-19 : what is the role of the hemostasis laboratory?
COVID-19 is associated with disturbances of hemostasis in the laboratory and an increased thrombotic risk. Routine laboratory tests - activated partial thromboplastin time (aPTT), prothrombin time, Clauss fibrinogen and D-dimers levels measurement - are used for the evaluation of the thrombotic risk and the monitoring of hemostasis, but are subject to several drawbacks that may affect the reliability and clinical relevance of the delivered results. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment. For instance, the issue of the monitoring of unfractionated heparin remains debated, the more so when there is a tremendous inflammatory response. This brief review considers the role of laboratory tests of hemostasis in the management of COVID-19 and discusses their main limitations to be kept in mind.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Annales de biologie clinique - 78(2020), 5 vom: 01. Okt., Seite 471-481 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Apport du laboratoire d’hémostase dans la gestion du risque thrombotique associé au Covid-19 |
|---|
| Beteiligte Personen: |
Hardy, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 19.10.2020 Date Revised 28.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/abc.2020.1581 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315964987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315964987 | ||
| 003 | DE-627 | ||
| 005 | 20231225160044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1684/abc.2020.1581 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM315964987 | ||
| 035 | |a (NLM)33026344 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Hardy, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of the thrombotic risk associated with COVID-19 |b what is the role of the hemostasis laboratory? |
| 246 | 3 | 3 | |a Apport du laboratoire d’hémostase dans la gestion du risque thrombotique associé au Covid-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2020 | ||
| 500 | |a Date Revised 28.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a COVID-19 is associated with disturbances of hemostasis in the laboratory and an increased thrombotic risk. Routine laboratory tests - activated partial thromboplastin time (aPTT), prothrombin time, Clauss fibrinogen and D-dimers levels measurement - are used for the evaluation of the thrombotic risk and the monitoring of hemostasis, but are subject to several drawbacks that may affect the reliability and clinical relevance of the delivered results. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment. For instance, the issue of the monitoring of unfractionated heparin remains debated, the more so when there is a tremendous inflammatory response. This brief review considers the role of laboratory tests of hemostasis in the management of COVID-19 and discusses their main limitations to be kept in mind | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a D-dimers | |
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a coagulopathy | |
| 650 | 4 | |a thrombosis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Lessire, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Chatelain, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Testa, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Gouin-Thibault, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gruel, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Lecompte, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales de biologie clinique |d 1945 |g 78(2020), 5 vom: 01. Okt., Seite 471-481 |w (DE-627)NLM000026344 |x 1950-6112 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2020 |g number:5 |g day:01 |g month:10 |g pages:471-481 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/abc.2020.1581 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2020 |e 5 |b 01 |c 10 |h 471-481 | ||